EichorEICHOR
Study identifier: NCT06788509 Synced from ClinicalTrials.gov · August 04, 2026
● Enrolling By Invitation

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Condition: Leukemia, Myeloid, Acute · Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Non-Hodgkin  ·  Sponsor: Janssen Research & Development, LLC

PhasePhase 1
Planned participants120
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to collect long-term safety data in participants with cancers including acute myeloid leukemia, non-Hodgkin lymphoma, myelodysplastic syndrome, chronic lymphocytic leukemia (type of cancer of the blood and bone marrow in which the bone marrow makes a large number of abnormal blood cells) and advanced solid tumors and metastatic castration-resistant prostate cancer (mCRPC).

This description comes directly from the study's public registry record.

Talk to the study team

No contact information is available for this study as per the public registry record.

Always discuss trial participation with your own doctor first.

Locations (36)

Macquarie University HospitalMacquarie University, Australia
Linear Clinical Research LtdNedlands, Australia
Scientia Clinical ResearchRandwick, Australia
Ghent University HospitalGhent, Belgium
Hopital Claude HuriezLille, France
CHU NantesNantes, France
Institut Gustave RoussyVillejuif, France
Arensia Exploratory MedicineTbilisi, Georgia
Alexandra HospitalAthens, Greece
Rambam Med.Center - Hematology InstituteHaifa, Israel
Rambam Medical CenterHaifa, Israel
Carmel Medical CenterHaifa, Israel

+ 24 more locations — full list on the registry record.

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →